Compare PLPC & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLPC | AMLX |
|---|---|---|
| Founded | 1947 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2001 | 2021 |
| Metric | PLPC | AMLX |
|---|---|---|
| Price | $269.69 | $13.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $275.00 | $20.11 |
| AVG Volume (30 Days) | 133.8K | ★ 867.2K |
| Earning Date | 03-04-2026 | 03-03-2026 |
| Dividend Yield | ★ 0.32% | N/A |
| EPS Growth | N/A | ★ 65.46 |
| EPS | ★ 7.14 | N/A |
| Revenue | N/A | ★ $380,786,000.00 |
| Revenue This Year | $17.19 | N/A |
| Revenue Next Year | $7.28 | N/A |
| P/E Ratio | $36.90 | ★ N/A |
| Revenue Growth | N/A | ★ 1612.94 |
| 52 Week Low | $128.23 | $3.11 |
| 52 Week High | $287.97 | $17.49 |
| Indicator | PLPC | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 54.74 | 48.61 |
| Support Level | $209.15 | $13.36 |
| Resistance Level | $282.99 | $15.37 |
| Average True Range (ATR) | 13.00 | 0.74 |
| MACD | 0.81 | -0.08 |
| Stochastic Oscillator | 66.25 | 48.17 |
Preformed Line Products Co is a designer and manufacturer of products and systems for constructing and maintaining overhead and underground networks for energy, telecommunication, cable operators, data communication, and other industries. The Company's primary products support, protect, connect, terminate, and secure cables and wires. The Company provides helical solutions, connectors, fiber optic and copper splice closures, solar framing applications, and electric vehicle charging station foundations. The Company's customers include public and private energy utilities and communication companies, cable operators, contractors and subcontractors, distributors, and value-added resellers. Geographically, the company operates in four regions: PLP-USA, the Americas, EMEA, and Asia-Pacific.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.